Gabriel De Avila

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima et al. · Journal of Clinical Oncology · 2025 · 35 citations · Full text

Medicine, Immunology, Oncology +16

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience

Hamza Hashmi, Doris K. Hansen, Lauren C. Peres et al. · Haematologica · 2023 · 34 citations · Full text

Medicine, Hematology, Immunology +16

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

Ciara L. Freeman, Jerald Noble, Meghan Menges et al. · Blood · 2024 · 33 citations

Medicine, Hematology, Oncology +17

Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy

Lauren C. Peres, Laura B. Oswald, Christen Dillard et al. · Blood Advances · 2023 · 27 citations · Full text

Medicine, Hematology, Immunology +16

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

AGM Mostofa, Allison Distler, Mark B. Meads et al. · JCI Insight · 2021 · 23 citations · Full text

Medicine, Oncology, Pharmacology +15